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OBJECTIVES This study analyzes the relationship between pacing mode and long-term survival in a large
group of very elderly patients ($80 years old).
BACKGROUND The relationship between pacing mode and long-term survival is not clear. Because the
number of very elderly who are candidates for pacing is increasing, issues related to pacemaker
(PM) use in the elderly have important clinical and economic implications.
METHODS We retrospectively reviewed 432 patients (mean age, 84.5 6 3.9 years) who received their
initial PM (ventricular in 310 and dual chamber in 122) between 1980 and 1992. Follow-up
was complete (3.5 6 2.6 years). Observed survival was estimated by the Kaplan-Meier
method. Age- and gender-matched cohorts from the Minnesota population were used for
expected survival. Log-rank test and Cox regression hazard model were used for univariate
and multivariate analyses.
RESULTS Patients with ventricular PMs appeared to have poor overall survival compared with those
with dual-chamber PMs. Observed survival after PM implantation in high grade atrioven-
tricular block (AVB) patients was significantly worse than expected survival of the age- and
gender-matched population (p , 0.0001), whereas observed survival of patients with sinus
node dysfunction was not significantly different from expected survival of the matched
population (p 5 0.413). By univariate analysis, ventricular pacing in patients with AVB
appeared to be associated with poor survival compared with dual-chamber pacing (hazard
ratio [HR] 2.08; 95% confidence interval [CI] 1.33 to 3.33). After multivariate analysis, this
difference was no longer significant (HR 1.41; 95% CI 0.88 to 2.27). Independent predictors
of all-cause mortality were number of comorbid illnesses, New York Heart Association
functional class, left ventricular depression and older age at implant. Pacing mode was not an
independent predictor of overall survival. Older age at implantation, diabetes mellitus,
dementia, history of paroxysmal atrial fibrillation and earlier year of implantation were
independent predictors of ventricular pacemaker selection.
CONCLUSIONS After PM implantation, long-term survival among very elderly patients was not affected by
pacing mode after correction of baseline differences. Selection bias was present in pacing
mode in the very elderly, with ventricular pacing selected for sicker and older patients, perhaps
partly explaining the apparent “beneficial impact on survival” observed with dual-chamber
pacing. (J Am Coll Cardiol 1999;33:1208–16) © 1999 by the American College of
Cardiology
More than 85% of pacemaker (PM) recipients in the United
States are older than 65 years (1). As life expectancy of the
population steadily increases, issues related to PM use in the
elderly will have a greater socioeconomic impact (2). The
selection of the pacing system has important clinical and
economic implications—sophisticated devices are more ex-
pensive and complex when compared with single-chamber
PMs and require more frequent follow-up. Whether the
increased cost, complexity and frequent follow-up required
by these pacing systems offset the known or suspected
clinical benefits in the very elderly is not clear.
The beneficial impact of pacing mode in symptomatic
conduction system disease has been well documented (3–8).
By maintaining atrioventricular (AV) synchrony, atrial or
dual-chamber pacing has been suggested to confer a phys-
iologic advantage (9) over single-chamber ventricular pac-
ing. Physiologic pacing may reduce morbidity by decreasing
the incidence of atrial fibrillation (10–13), thromboembolic
phenomena (6,13) and congestive heart failure (12,14) and
affect the quality of life by improving effort tolerance and
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general well-being (9). However, the effect of pacing mode
on long-term survival, especially in the very elderly, is not
clear. The impact of pacing mode in octogenarians and
nonagenarians is more difficult to establish because of the
high prevalence of coexisting illnesses, the nonspecific
nature of symptoms, shorter life expectancy and limited
availability of long-term follow-up data. Most of the sur-
vival studies in this age group are short-term, retrospective
analyses of small numbers of patients with incomplete
follow-up. Moreover, multivariate analytic techniques have
not been used to adjust for baseline differences between
patient groups with different pacing modalities. Hence, the
impact of pacing mode on overall survival in the very elderly
remains uncertain.
In the present study, the differential impact of pacing
mode (ventricular vs. dual chamber) on long-term survival
in a large group of octogenarians and nonagenarians was
examined. Multivariate analysis was used to adjust for
baseline characteristics. Factors predictive of long-term
survival and those influencing the selection of the pacing
mode were also assessed.
METHODS
Study population. The study population consisted of all
patients 80 years and older who received their initial PM at
the Mayo Clinic between January 1980 and December
1992. These patients were categorized according to the
presence of sinus node dysfunction (SND) or high grade
atrioventricular block (AVB) (Table 1). Sinus node dysfunc-
tion was defined by the presence of inappropriate persistent
sinus bradycardia (,50 beats/min), sinus pauses longer than
3 s or sinoatrial block. High grade AVB was defined by the
presence of complete AVB or type II second-degree AVB.
Patients in chronic atrial fibrillation were excluded from
pacing mode comparison. The pacing mode was selected in
a nonrandomized fashion on the basis of the pacing physi-
cian’s appraisal of a patient’s need.
Data collection and follow-up. Data were obtained retro-
spectively from a centralized system of records of PMs
implanted and followed up at the Mayo Medical Center.
Each patient was followed up after PM implantation up to
December 31, 1993, or the time of death before January 1,
1994. Follow-up information was obtained by review of the
medical records or by telephone interview of patients and
their families. Causes of death were grouped as
“cardiovascular-related” (sudden death, refractory ventricu-
lar arrhythmia, heart failure, myocardial infarction, periph-
eral embolism), “cerebrovascular disease” (stroke), “noncar-
diovascular” (any other documented cause) or “unknown.”
Statistical analysis. Multivariate and univariate models to
predict pacing mode were completed using logistic regres-
sion models. Survival after permanent pacemaker implanta-
tion was estimated with the Kaplan–Meier method. Ex-
pected survival was completed separately for each subgroup
of patients with AVB or SND based on life tables for death
from all causes from the Minnesota population for people of
like age, gender and calender year of birth. Within-group
comparisons of observed to expected survival were com-
pleted using the one-sample log-rank test. Two-group
survival curve comparisons were based on the two-sample
log-rank test. Univariate and multivariate associations of
baseline variables with survival were assessed using the
log-rank test and the Cox regression model (15). Multivar-
iate models are summarized in the form of point estimates
and 95% confidence intervals on the multivariate hazard
ratios. Baseline variables considered as potential prognostic
factors are listed in Table 2.
RESULTS
Patient demographics and pacemaker selection. A total
of 584 patients 80 years and older received a permanent PM
at the Mayo Clinic between January 1980 and December
1992. All patients with chronic atrial fibrillation or carotid
Abbreviations and Acronyms
AV 5 atrioventricular
AVB 5 atrioventricular block
CI 5 confidence interval
NYHA 5 New York Heart Association
PM 5 pacemaker
SND 5 sinus node dysfunction
Table 1. Indications for Pacemaker Implantation in Octogenarians and Nonagenarians, 1980 to
1992
Demographic Feature
Atrioventricular
Block
Sinus Node
Dysfunction Other* Total
No. of patients 276 (64%) 141 (33%) 15 (3%) 432
Mean age 6 SD (yr) 84.5 6 3.9 84.5 6 3.9 83.4 6 2.9 84.5 6 3.9
No. of men 153 (55%) 59 (42%) 10 (67%) 222 (51%)
Pacing mode (no. of patients)
Ventricular 196 (71%) 101 (72%) 13 (87%) 310 (72%)
Dual chamber 80 (29%) 40 (28%) 2 (13%) 122 (28%)
*Includes syncope of undetermined cause.
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sinus hypersensitivity (n 5 152) were excluded from pacing
mode comparison, leaving 432 patients for analysis (51%
men and 49% women) (Table 1, Fig. 1). The mean age of
the study group was 84.5 6 3.9 years (range, 80 to 99 years).
There were 276 patients (64%) with high grade AVB, 141
(33%) with SND and 15 (3%) with other indications,
including syncope of undetermined cause (Table 1). In
patients with high grade AVB, the pacing mode was
ventricular in 196 (71%) and dual chamber in 80 (29%). In
patients with SND, the pacing mode was ventricular in 101
(72%) and dual chamber in 40 (28%). The proportion of
dual-chamber PMs implanted increased each year, from 5%
in 1980 to 33% in 1985 to 39% in 1992. The baseline
characteristics of patients who received single-chamber or
dual-chamber pacing devices are summarized in Table 2.
The patients were followed for a mean of 3.5 (62.6)
years. For those who survived, mean follow-up was 4.5
(62.5) years, with maximum follow-up to 10.9 years.
Up-to-date medical records of all 432 patients were re-
viewed. All surviving patients (n 5 194) and physicians or
family members of deceased patients (n 5 238) were
followed by telephone interview.
Overall survival and survival from cardiovascular mor-
tality. Observed overall survival in the very elderly with
symptomatic conduction system disease who had ventricular
pacing devices was significantly worse than that of patients
with dual-chamber pacing devices (p 5 0.0003). Overall
survival for the entire study group with respect to pacing
mode is shown in Figure 2. Observed survival in the
ventricular pacing group at 1, 3 and 5 years was 80%, 57%
and 45%, respectively, compared with 92%, 76% and 58%
for the dual-chamber pacing group.
Observed survival curves after PM implantation for pa-
Table 2. Baseline Characteristics of Octogenarians and Nonagenarians Who Had Dual-
Chamber or Ventricular Pacemakers Implanted Between 1980 and 1992
Characteristic
Dual Chamber
(n 5 122)
Ventricular
(n 5 310) p Value
Mean age at implantation (yr) 83.3 6 3.13 84.95 6 4.07 ,0.001
Disease risk score 1.11 6 0.96 1.37 6 1.08 0.02
Follow-up (yr) 3.4 6 2.6 3.8 6 2.4 0.04
No. of men 67 (54.9%) 154 (49.8%) NS
Sum of cardiac medications (no.) 1.61 6 1.31 1.74 6 1.35 NS
Organic brain syndrome (%) 3 14 0.001
Prosthetic valve (%) 10 3 0.003
Diabetes mellitus (%) 6 14 0.01
Previous cardiac surgery (%) 17 9 0.01
Stroke/transient ischemic attack (%) 10 18 0.05
Atrioventricular block (%) 66 63 NS
Sinus node dysfunction (%) 32 33 NS
Myocardial infarction (%) 22 29 NS
Angina pectoris (%) 33 37 NS
Cardiomyopathy (%) 17 15 NS
Left ventricular depression
(moderate–severe) (%)
16.4 14.6 NS
Congestive heart failure, NYHA class (%) NS
I 66 60 NS
II 20 28 NS
III–IV 14 12 NS
Paroxysmal atrial fibrillation (%) 25 31 NS
Hypertension (%) 57 51 NS
Renal disease (%) 7 11 NS
Chronic obstructive lung disease (%) 11 9 NS
Peripheral vascular disease (%) 13 13 NS
Active cancer (%) 5 6 NS
Living arrangement (%)
Live alone 37 40 NS
Retirement home 2 3 NS
Nursing home 2 10 0.002
Supraventricular tachycardia (%) 24 18 0.20
Ventricular tachycardia (%) 17 16 NS
History of cancer (%) 23 20 NS
NYHA 5 New York Heart Association.
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tients with AVB and those with SND and expected survival
curves for their age- and gender-matched control popula-
tions are shown in Figure 3. In patients with AVB,
cumulative survival after permanent PM implantation was
significantly worse than expected survival in the general
population (p , 0.0001, Fig. 3A). Observed survival at 1, 3
and 5 years was 83%, 61% and 47%, respectively, compared
with 90%, 71% and 54% for the control population. In
elderly patients with SND, observed survival after PM
implantation was comparable to expected survival for the
matched population (p 5 0.413, Fig. 3B). At 1, 3 and 5
years, the observed survival after PM implantation for
patients with SND was 83%, 63% and 52%, respectively,
compared with 90%, 72% and 55% for the matched popu-
lation.
The impact of pacing mode on long-term survival of very
elderly patients with high grade AVB is shown in Figure 4.
Patients who had single-chamber ventricular pacing had
significantly worse survival outcome compared with patients
with dual-chamber pacing (p 5 0.0001; risk ratio 0.445;
95% confidence interval [CI] 0.293 to 0.674). Observed
survival of patients with AVB and dual-chamber pacing at
five years was 62%, compared with 41% for those with
ventricular pacing. For patients with SND, no significant
Figure 1. Permanent pacemaker implantation in octogenarians
and nonagenarians between 1980 and 1992. Patients with chronic
atrial fibrillation or carotid sinus hypersensitivity were excluded.
Figure 2. Long-term overall survival in octogenarians and non-
agenarians after implantation of a dual-chamber or ventricular
pacemaker. The observed survival in patients with a ventricular
pacemaker is significantly worse than those with a dual-chamber
pacemaker. The numbers below the graph indicate the number of
patients at risk at each point.
Figure 3. A: Observed survival in patients with high grade
atrioventricular block was significantly worse than expected sur-
vival of control population. B: Observed survival in patients with
sinus node dysfunction was similar to expected survival of control
population.
Figure 4. Long-term survival rates in the octogenarians and
nonagenarians with high grade atrioventricular block after implan-
tation of ventricular or dual-chamber pacemaker.
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difference was seen in overall survival between the two
pacing modes (risk ratio 0.711; 95% CI 0.418 to 1.210)
(Fig. 5).
During follow-up, 238 patients died (48 patients with
dual-chamber PMs and 190 with ventricular PMs). The
causes of death are summarized in Table 3. One hundred
fifteen patients (48.3%) died of cardiovascular-related causes
(22 with dual-chamber PMs and 93 with ventricular PMs),
121 (50.8%) of noncardiovascular causes and 2 (0.8%) of
unknown cause. There was no difference in the causes of
death between the two pacing groups. Survival from
cardiovascular-related mortality was 86%, 73% and 67% at
1, 3 and 5 years, respectively, in the ventricular pacing group
and 96%, 89% and 74% in the dual-chamber pacing group.
The most common cause of cardiac death in this patient
population was congestive heart failure (49% of cardiovas-
cular deaths) (Table 3). However, there was no significant
difference in terms of mortality due to congestive heart
failure between the two pacing groups.
Univariate and independent predictors of overall sur-
vival. The univariate predictors of overall and cardiovascu-
lar mortality are summarized in Table 4. To minimize the
effect of selection bias, the Cox proportional hazard regres-
sion model was used for adjustment of possible baseline
differences and to identify independent predictors of poor
survival. The independent predictors of overall survival and
survival from cardiovascular-related death, with risk ratios
and 95% confidence intervals, are summarized in Table 5.
The mode of pacing (ventricular vs. dual chamber) was not
an independent predictor of overall survival. The difference
in overall survival in patients with AVB initially seen
between the two pacing mode groups disappeared after this
adjustment. Independent predictors of poor survival at the
time of initial PM implantation were the number of
comorbid illnesses, New York Heart Association (NYHA)
functional class, left ventricular depression and older age.
Predictors of PM selection. Independent predictors asso-
ciated with PM selection identified by multivariate analysis
are summarized in Table 6. Patients who received a dual-
chamber PM were younger than those who received a
ventricular PM, with a mean age of 83.3 years compared
with 85 years in the ventricular PM group (p , 0.001) (Fig.
1). There was no significant difference in PM selection
between the two genders. The dual-chamber system was
selected more frequently for patients who had previous
cardiac surgery (p 5 0.01) or prosthetic valve (p 5 0.003).
Patients with diabetes mellitus (p 5 0.02) or a history of
stroke or transient ischemic attack (p 5 0.05) or organic
brain syndrome (p 5 0.001) or those with comorbid
illnesses (p 5 0.02) more frequently received single-
chamber ventricular devices. There was no significant dif-
ference between the two groups (Table 2) with regard to the
underlying cardiac disease.
DISCUSSION
The results of the present study indicate that overall survival
of very elderly patients with high grade AVB was worse than
the expected survival of an age- and gender-matched pop-
ulation. However, observed survival after PM implantation
in patients with SND was comparable to the expected
survival of the matched population. In elderly patients with
SND, no significant difference in overall, cardiovascular or
noncardiovascular mortality was observed in patients receiv-
ing a ventricular or a dual-chamber PM. In patients with
high grade AVB, ventricular pacing was associated with an
increased risk of overall and cardiovascular mortality by
univariate analysis. However, after adjustment of the base-
line differences with multivariate analysis, the mode of
pacing was no longer an independent predictor of overall
mortality. Age at implantation, left ventricular depression,
NYHA functional class and number of comorbid illnesses
were independent predictors of poor overall survival.
Figure 5. Long-term survival rates in octogenarians and nonage-
narians with sinus node dysfunction after implantation of a
ventricular or dual-chamber pacemaker.
Table 3. Causes of Death Among 432 Octogenarians and
Nonagenarians Who Had a Pacemaker Implanted Between
1980 and 1992*
Cause No. (%)
Cardiovascular 115 (48.3)
Congestive heart failure 56
Myocardial infarction 21
Sudden death 14
Unclassified cardiovascular cause 24
Noncardiovascular 121 (50.8)
Stroke 23
Other 98
Unknown 2 (0.8)
Total 238 (100)
*Pacemakers were implanted for symptomatic conduction disease; patients with
chronic atrial fibrillation or carotid sinus hypersensitivity were excluded.
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Long-term survival in patients with sinus node dysfunc-
tion. Several studies in patients with SND treated with
single-chamber fixed-rate ventricular pacing have demon-
strated an apparent increase in complications compared
with those treated with atrial or dual-chamber pacing
(13,14,16). These complications include PM syndrome,
lack of AV synchrony and physiologic heart rate response to
exercise, development of atrial fibrillation and systemic
embolization (6,10,11). Physiologic pacing (atrial or dual
chamber) has been shown to improve hemodynamics and
exercise tolerance (9) in the short term and has been
suggested to reduce morbidity by decreasing the occurrence
of atrial fibrillation (6,11), heart failure (12,14) and throm-
boembolic phenomena (6,7,16–19). Critical review of the
Table 4. Univariate Predictors of Mortality
Overall Mortality
Cardiovascular
Mortality
Risk
Ratio 95% CI
Risk
Ratio 95% CI
Demographics
Male gender 1.36 1.05, 1.76 1.43 0.99, 2.08
Age at implantation 1.09 1.06, 1.12 1.07 1.03, 1.12
Coexisting medical illnesses
Renal disease 2.49 1.70, 3.64 2.83 1.70, 6.70
COPD 2.04 1.39, 2.98 2.98 1.87, 4.75
Dementia 2.01 1.41, 2.87 1.47 0.84, 2.58
Active cancer 1.96 1.19, 3.21 0.82 0.30, 2.22
Peripheral vascular disease 1.83 1.31, 2.55 1.55 0.95, 2.54
Stroke/transient ischemic attack 1.52 1.10, 2.09 1.71 1.10, 2.67
Diabetes mellitus 1.47 1.02, 2.12 1.00 0.55, 1.83
Number of comorbidities 1.48 1.32, 1.66 1.37 1.21, 1.55
Coexisting heart disease
NYHA 1.66 1.40, 1.95 2.15 1.72, 2.69
Nonsustained ventricular tachycardia 1.59 1.14, 2.22 2.26 1.48, 3.45
Left ventricular dysfunction 1.41 1.22, 1.66 1.56 1.30, 1.87
Myocardial infarction within six
months before pacing
1.59 1.02, 2.46 2.53 1.51, 4.24
History of myocardial infarction 1.41 1.07, 1.87 1.90 1.30, 2.78
Cardiomyopathy 1.56 1.14, 2.14 1.68 1.08, 2.60
Number of cardiac medications 1.14 1.04, 1.25 1.37 1.21, 1.55
Mode of pacing
Dual chamber vs. ventricular 0.56 0.40, 0.77 0.51 0.32, 0.80
CI 5 confidence interval; COPD 5 chronic obstructive pulmonary disease; NYHA 5 New York Heart Association.
Table 5. Independent Predictors of Poor Survival From Total and Cardiovascular-Related
Deaths After Pacemaker Implantation in Octogenarians and Nonagenarians, 1980 to 1992,
Multivariate Model for Survival*
Variable
Overall Mortality
Cardiovascular
Mortality
Risk
Ratio 95% CI
Risk
Ratio 95% CI
Disease risk score 1.664 1.449, 1.910 1.350 1.047, 1.149
NYHA class 1.506 1.267, 1.789 1.948 1.527, 2.485
Left ventricular depression 1.246 1.074, 1.445 1.311 1.083, 1.588
Age at implantation 1.102 1.069, 1.137 1.097 1.047, 1.149
COPD 1.790 1.064, 3.010
Myocardial infarction within six
months before pacing
1.758 1.021, 3.029
AV block 1.046 0.795, 1.374 0.863 0.583, 1.278
*Angina, cardiomyopathy, paroxysmal atrial fibrillation, diabetes mellitus and stroke/transient ischemic attack were not
significant predictors.
AV, atrioventricular; other abbreviations as in Table 4.
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literature of SND indicates that the clinical and survival
benefit of physiologic pacing over ventricular pacing is
apparently inconclusive (18–21). The conclusions of most
of the studies that suggest a deleterious effect from ventric-
ular pacing should be interpreted in light of their limita-
tions; most were nonrandomized, retrospective studies lim-
ited by the inability to control for important baseline clinical
differences between patients with different pacing modes
(6,11,22). In most of the studies, the rationale for selecting
different pacing modes was not documented, and differences
in cardiovascular and noncardiovascular comorbid condi-
tions were not considered. The increased morbidity and
mortality in patients with ventricular pacing may well be
related to the underlying cardiovascular disease, coexisting
noncardiac condition and age rather than the pacing system
selected and, thus, may reflect selection bias. Furthermore,
the study follow-up periods for different pacing modes were
either incomplete or different and, therefore, difficult to
compare. Recent studies in younger patients with SND have
used multivariate techniques to control for baseline differ-
ences and have demonstrated no significant worsening effect
of ventricular pacing on heart failure (20) or on overall or
cardiovascular mortality (10,19,21). Our results confirm and
extend these findings to octogenarians and nonagenarians,
namely, that ventricular pacing does not appear to have a
negative impact on overall survival or survival from cardio-
vascular mortality in patients with SND.
Long-term survival in patients with AV block. The one-
and five-year cumulative survival rates of 83% and 47%,
respectively, observed in our study of patients with AVB, are
worse than the expected survival of 90% and 54%, respec-
tively, of an age- and gender-matched Minnesota popula-
tion. The observed survival rates in our group with AVB are
comparable to those reported by Strauss and Berman (3) in
the Canadian population and by Elizabeth and Green (23)
in the British population. These survival rates are better
than that reported by Breivik and Ohm (4) in the Norwe-
gian population. The explanation for the different outcomes
is not known, but it most likely reflects different indications
for pacing, patient selection criteria, presence and severity of
underlying heart disease and dates of the studies. The causes
of mortality in patients with AVB in our study were
multifactorial, with a significant number dying of noncar-
diovascular causes.
In a recent retrospective analysis of a random sample of
36,312 Medicare beneficiaries 65 years and older, dual-
chamber pacing was an independent predictor of survival at
one and two years after PM implantation (24). In other
studies of patients without congestive heart failure, however,
the survival rate was not significantly different for patients
with ventricular pacing and those with dual-chamber pacing
(25,26). With preexisting heart failure, patients with dual-
chamber pacing appear to have a better survival outcome
compared with those with ventricular pacing (26). In the
present study of patients 80 years and older, the relative
survival after PM implantation for AVB appears to be poor
regardless of the presence of heart disease. Observed survival
was significantly worse than expected, both for patients with
and for those without associated underlying heart disease.
This is consistent with the observation that the causes of
mortality in the very elderly are likely multifactorial, as
reflected in the significant number of deaths due to noncar-
diac causes (;51% of all deaths) and will not be significantly
affected by PM (Table 3).
Pacemaker selection. Advancing age in our very elderly
population was associated with decreased use of dual-
chamber pacing. This is consistent with findings by others
(24,27) and reflects the existing practice that emphasizes the
use of more expensive and complicated devices and inter-
ventions in active, younger patients. Despite demonstrable
hemodynamic advantages and suggested clinical benefits of
dual-chamber pacing, ventricular pacing is still the most
frequently used pacing modality (1), especially in the very
elderly. This discrepancy between the suggested potential
benefits and the pacing practice suggests that physicians
implanting PMs are often less aggressive in the very elderly
and choose simpler, less expensive devices, perhaps because
of the lack of data specifically addressing the elderly or
because of the attitude that more complex, expensive,
sophisticated interventions are of “limited use” in this group
(28). Factors other than the chronologic age, such as
functional ability, activity level, coexisting illnesses and life
expectancy, are important in selecting a pacing mode.
Clinical implications. In our study, dual-chamber pacing
mode in the very elderly population was not an independent
predictor of overall survival or survival from cardiovascular
mortality. The apparent differences in overall survival seen
with pacing mode in patients with AVB reflected a selection
bias of choosing ventricular pacing for sicker patients. In
this study, we did not analyze the effect of PM mode on the
incidence of atrial fibrillation, thromboembolism, conges-
tive heart failure or quality of life.
With the current cost-containment environment, in-
crease in the aging population and the competition for
shrinking resources, long-term clinical outcomes provide
needed information in guiding therapeutic recommenda-
tions. Despite lack of data (at this time) convincingly
Table 6. Predictors of Dual-Chamber Pacemaker Selection in
the Very Elderly, 1980 to 1992
Variable
Odds
Ratio 95% CI
Organic brain syndrome 0.257 0.09, 0.75
Diabetes mellitus 0.394 0.17, 0.92
Paroxysmal atrial fibrillation 0.60 0.36, 0.99
Age at implantation 0.88 0.82, 0.94
Nursing home 0.242 0.05, 1.07
Year of implantation 1.10 1.03, 1.17
Prosthetic valve 2.39 0.94, 6.10
CI 5 confidence interval.
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showing a beneficial effect on survival, chronologic age alone
should not be considered a bar to the use of sophisticated
PMs when a clear beneficial effect can be established.
Octogenarians and nonagenarians belong to a highly
heterogeneous group with respect to the presence of coex-
isting medical illnesses, severity of cardiac diseases and
functional capabilities. The relative survival is inversely
related to coexisting underlying heart disease and medical
illness. Pacing mode selection in the elderly or in any
population must be individualized—with careful prescrip-
tion according to activity level, underlying rhythm disorders
and cardiovascular and noncardiac comorbidities—to pro-
vide optimal functional benefit with minimal complications
related to inappropriate pacing and cost. In patients with
AVB and SND with coexisting heart disease, the assess-
ment of benefits from physiologic pacing is an important
area for further investigation. Results from ongoing pro-
spective trials comparing single-chamber with dual-
chamber pacing will help to better understand the func-
tional status, quality of life, cost-effectiveness, morbidity and
survival benefits after long-term ventricular and physiologic
pacing in the overall and rapidly expanding elderly popula-
tions. Cost reductions may be achieved by minimizing the
use of complex systems in the very elderly who have limited
mobility (e.g., musculoskeletal disease or neurologic defi-
cits), a terminal illness or symptoms that are infrequent,
intermittent or vague. For others, improvement in cardiac
output and quality of life with physiologic pacing may be a
crucial factor in allowing continued independence and
potential decrease in the number of hospital visits and
medical treatment for atrial fibrillation, heart failure (with
systolic or diastolic dysfunction), thromboembolic phenom-
ena or other morbidity. It is important to note that no
significant quality of life benefits were observed in the
elderly with dual-chamber pacing mode from a recent
prospective randomized trial (29).
Limitations. Our observations and conclusions should be
interpreted in light of the limitations imposed by the
retrospective nature of the study. Pacemaker selection was
not randomized, and unknown, undocumented confound-
ing variables that could not be determined by a retrospective
review of the medical records may have led clinicians to
select one device over the other. The multivariate model was
used in our study to minimize the effect of baseline
differences. Although all the clinical records were inter-
preted and translated into a standard data format, most of
the information was qualitative. In particular, left ventricu-
lar function was not routinely measured in all patients, and
the anatomical severity of coronary artery disease was not
routinely determined. Moreover, considerable advances
were made in PM and lead technology in the 1980 to 1992
period, along with improvement in management of patients
with cardiovascular disease, which could have affected clin-
ical outcomes and overall survival.
In contrast to many of the previously reported studies, a
strong point of our analysis is the use of multivariate
techniques to adjust for baseline characteristics of the
patients to minimize the impact of selection bias. In
addition to being a complete sample (no patient was lost to
follow-up) of all initial PM implantations in a relatively
large group of octogenarians and nonagenarians, another
strength of our study is the careful evaluation of the impact
of coexisting heart disease and medical illnesses on survival
after pacemaker implantation.
Conclusions. In our study, after correction for baseline
differences, long-term survival among octogenarians and
nonagenarians after PM implantation for AVB or SND was
not affected by pacing mode. Selection bias was present in
the very elderly, with ventricular pacing selected for older,
sicker patients, perhaps partly explaining the apparent “ben-
eficial impact on survival” observed with direct chamber
pacing in healthier, “younger” elderly patients.
Reprint requests and correspondence: Dr. Win-Kuang Shen,
Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
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